Erasca announces ERAS-0015 data: what it means for Erasca stock

Published on 10/06/2026 at 06:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Phase one data showed a 57.00 percent eight-week response rate. Eight of 11 analysts rate Erasca stock a Buy, with market value at USD 5.1 billion.

ERAS, US29479A1088, Illustration mit AI erstellt.

Erasca (ISIN US29479A1088) reported a 57.00 percent eight-week response rate for ERAS-0015 in second-line or later pancreatic cancer, while a September 10, 2026 release scheduled expanded clinical data for presentation. The update gives Erasca stock a clear next milestone, but the program remains in Phase 1 development.

What the new data means

According to Erasca on September 10, 2026, updated monotherapy data from the AURORAS-1 Phase 1 trial will be presented at the 38th EORTC-NCI-AACR Symposium in Barcelona from November 18 to November 20, 2026. The company also plans to present nonclinical combination data for ERAS-0015 and ERAS-4001.

The response rate is based on preliminary clinical data, not a registration-enabling or approval study. The same company release said the expanded presentation would include more patients and longer follow-up, making durability and safety important measures for the next readout.

Analyst view meets clinical risk

MarketBeat reported on October 3, 2026 that eight of 11 analysts rated Erasca a Buy, two rated it a Hold and one rated it a Sell. The average 12-month target was USD 22.09, while the latest reported opening price in that article was USD 14.74.

MarketBeat also reported diluted earnings per share of negative USD 0.14 for the quarter announced on August 11, 2026, versus a consensus estimate of negative USD 0.11. The result underlines the central valuation tension: the investment case depends on clinical progress rather than product revenue.

ERAS market position

Nasdaq-listed ERAS had a market capitalization of USD 5.1 billion as of October 5, 2026. Its 52-week range was USD 2.10 to USD 24.28 on the same date, placing the current market picture well above the annual low while leaving clinical execution as the key operating variable.

Erasca describes itself as a clinical-stage precision oncology company developing therapies for cancers driven by the RAS/MAPK pathway. Its pipeline includes ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor, with both programs still dependent on future clinical evidence.